DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Thyquidity is a drug marketed by EMP and is included in one NDA. There is one patent protecting this drug.
This drug has eleven patent family members in eleven countries.
The generic ingredient in THYQUIDITY is levothyroxine sodium. There are ten drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.
A generic version of THYQUIDITY was approved as levothyroxine sodium by MYLAN on June 5th, 2002.
Summary for THYQUIDITY
Pharmacology for THYQUIDITY
|Drug Class||l-Thyroxine |
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Emp||THYQUIDITY||levothyroxine sodium||SOLUTION;ORAL||214047-001||Nov 30, 2020||RX||Yes||Yes||Start Trial||Start Trial||Y||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|